Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01258608
Recruitment Status : Completed
First Posted : December 13, 2010
Last Update Posted : February 16, 2018
Information provided by (Responsible Party):
GlaxoSmithKline ( Human Genome Sciences Inc., a GSK Company )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 31, 2013
  Actual Study Completion Date : November 29, 2017
  Certification/Extension First Submitted : July 10, 2014